Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma

BACKGROUND: Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth factor receptor alpha, RET, and KIT. This phase 2, single-arm, open-label multicenter study evaluated lenvatinib in advanced hepatocellular c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ikeda, Kenji, Kudo, Masatoshi, Kawazoe, Seiji, Osaki, Yukio, Ikeda, Masafumi, Okusaka, Takuji, Tamai, Toshiyuki, Suzuki, Takuya, Hisai, Takashi, Hayato, Seiichi, Okita, Kiwamu, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2016
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357473/
https://www.ncbi.nlm.nih.gov/pubmed/27704266
http://dx.doi.org/10.1007/s00535-016-1263-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5357473/
https://www.ncbi.nlm.nih.gov/pubmed/27704266
http://dx.doi.org/10.1007/s00535-016-1263-4

Ejemplares similares